Integra LifeSciences Holdings Corp.’s Buy Rating Reaffirmed at Jefferies Group (IART)
Integra LifeSciences Holdings Corp. (NASDAQ:IART)‘s stock had its “buy” rating restated by analysts at Jefferies Group in a research report issued to clients and investors on Tuesday, Analyst Ratings Net reports. They currently have a $54.00 price objective on the stock, up from their previous price objective of $46.00. Jefferies Group’s price objective points to a potential upside of 23.71% from the stock’s previous close.
Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 4.19% during mid-day trading on Tuesday, hitting $45.48. 169,137 shares of the company’s stock traded hands. Integra LifeSciences Holdings Corp. has a one year low of $30.87 and a one year high of $44.53. The stock has a 50-day moving average of $39.95 and a 200-day moving average of $37.88. The company has a market cap of $1.278 billion and a price-to-earnings ratio of 48.45.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.02. The company had revenue of $213.20 million for the quarter, compared to the consensus estimate of $214.05 million. During the same quarter in the previous year, the company posted $0.85 earnings per share. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. Analysts expect that Integra LifeSciences Holdings Corp. will post $2.53 EPS for the current fiscal year.
A number of other firms have also recently commented on IART. Analysts at Morgan Stanley downgraded shares of Integra LifeSciences Holdings Corp. from an “equal weight” rating to an “underweight” rating in a research note to investors on Wednesday, October 23rd. They now have a $40.00 price target on the stock. Separately, analysts at Barclays initiated coverage on shares of Integra LifeSciences Holdings Corp. in a research note to investors on Friday, October 4th. They set an “equal weight” rating and a $43.00 price target on the stock. Finally, analysts at Piper Jaffray Cos. upgraded shares of Integra LifeSciences Holdings Corp. from a “neutral” rating to an “overweight” rating in a research note to investors on Thursday, August 15th. They now have a $50.00 price target on the stock, up previously from $41.00. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. Integra LifeSciences Holdings Corp. currently has an average rating of “Hold” and a consensus price target of $43.35.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.